Bioventus Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BVS research report →
Range $18 – $19
Price Chart
About the company
Bioventus Inc. , a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
- CEO
- Robert Claypoole
- IPO
- 2021
- Employees
- 960
- HQ
- Durham, NC, US
Get TickerSpark's AI analysis on BVS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $676.53M
- P/E
- 11.76
- Fwd P/E
- 12.86
- PEG
- 0.02
- P/S
- 1.16
- P/B
- 2.83
- EV/EBITDA
- 8.79
- Div Yield
- 0.00%
- Gross Margin
- 68.29%
- Op Margin
- 10.15%
- Net Margin
- 9.78%
- ROE
- 27.23%
- ROIC
- 11.03%
Latest fiscal year · YoY change
- Revenue
- $568.09M-0.9%
- Gross Profit
- $382.43M-1.5%
- Op Income
- $58.55M
- Net Income
- $22.73M+167.8%
- EPS
- $0.34+165.4%
- OCF Growth
- +90.7%
- FCF Growth
- +89.0%
- 52W High
- $15.89
- 52W Low
- $6.47
- 50D MA
- $12.87
- 200D MA
- $11.11
- Beta
- 0.62
- RSI (14)
- 29
- Avg Volume
- 538.93K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Bioventus posted modest third-quarter growth and higher profitability, but trimmed full-year revenue guidance due mainly to BGS headwinds while reaffirming EPS and raising cash flow expectations.· November 2, 2026
- Q3 revenue rose 3% to $142 million, with pain treatments up 6% and international up 16%, while BGS declined and Exogen was softer.
- Adjusted EBITDA was $28 million with a 20% margin, up 70 basis points year over year; adjusted EPS was $0.17, up 13% from $0.15.
- Management said PRP and PNS are building momentum, with PRP disposable reorders ramping and PNS trial-to-permanent conversion exceeding plan.
- Ultrasonics delivered strong double-digit growth, and management expects continued acceleration into Q4 and 2027.
- Full-year revenue guidance was cut to $590 million to $595 million, but adjusted EPS guidance of $0.75 to $0.79 was reaffirmed and cash from operations guidance was raised to $84 million to $89 million.
Revenue in the third quarter was $142 million, up 3% year over year. Adjusted EBITDA was $28 million, up nearly $2 million year over year, with adjusted EBITDA margin of 20%, up 70 basis points versus last year. Adjusted EPS was $0.17 per diluted share, up 13% from $0.15 a year ago. Gross margin was 75%, slightly below the prior year period. For segment detail, global pain treatments revenue was $71 million, up 6%; surgical solutions revenue was $51 million, up 1%; restorative therapies revenue was $21 million, down 3%; and international revenue was $18 million, up 16% (18% constant currency). Cash from operations was $21 million, cash on hand was $31 million, and debt outstanding was $230 million. The company repaid $19 million of term loan debt in the quarter and $65 million year to date, ending with net debt below $200 million. Full-year 2026 guidance was updated to revenue of $590 million to $595 million, adjusted EPS of $0.75 to $0.79, and cash from operations of $84 million to $89 million (also presented as adjusted cash from operations in the same range, excluding strategic review cash impact). Management expects mid-single-digit revenue growth in Q4 and sequential acceleration.
Robert Claypoole said Bioventus is building on positive momentum, with encouraging leading indicators across the growth drivers and a strategy focused on revenue growth, earnings expansion, and stronger cash flow. He highlighted PRP, PNS, ultrasonics, and international as the key growth engines, emphasizing that PRP reorders are ramping, PNS physician engagement is improving, and ultrasonics is seeing strong adoption and disposable growth. He also said the strategic review is ongoing and would not be discussed further. His tone was constructive and confident, with repeated comments about transitory issues in BGS and strong long-term opportunity in the portfolio.
Mark Singleton emphasized that the company continued to increase profitability while investing in growth. He cited revenue of $142 million, adjusted EBITDA of $28 million, a 20% margin, and adjusted EPS of $0.17, while noting adjusted gross margin of 75% was slightly below last year mainly due to product mix. He said cash from operations totaled $21 million, debt was reduced by $19 million in the quarter to $230 million outstanding, and net leverage is expected to be below 1.5x by year-end. He also explained that BGS weakness affected guidance because it is the lowest variable-margin business, and said the company has accelerated investment from the planned $13 million to almost $15 million, with more than half going to PNS.
Analysts focused heavily on BGS weakness, asking whether the issue was primarily pricing/competition, how much it might affect ultrasonics, and whether the slowdown was isolated to specific products like Signifuse or broader across the portfolio. Management said the issues were primarily transitory, driven by competitive dynamics in the synthetic market and slower procedural volume/new distributor onboarding, and added that October was tracking ahead after corrective actions taken late in Q3. Analysts also pressed for more detail on PNS and PRP contribution, and management said those businesses are tracking a little shy of the original 200-basis-point lift target but are still ramping well. On the strategic review timing, management repeatedly declined to comment beyond saying the process is ongoing.
The call showed clear momentum in several growth drivers: PRP disposables are outpacing capital placements, PNS is seeing better-than-planned conversions and more trained physicians, ultrasonics is posting strong double-digit growth, and international accelerated 16%. Management sounded confident that these trends can drive sequential acceleration in Q4 and continued growth into 2027, while still producing higher earnings and cash flow. The balance sheet also improved meaningfully, with debt repayments and net debt below $200 million.
The main drag was BGS, where management cut full-year revenue guidance and pointed to competitive dynamics, slower spine procedures, and distributor timing issues. Exogen also faced headwinds from salesforce vacancies, and management said full-year growth there will land at the low end of its prior target range. The company is also increasing investment, which supports growth but can pressure near-term margins if revenue execution slips, and the strategic review remains unresolved, adding uncertainty around capital allocation and the company’s future path.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 69.2%
- Shares Outstanding
- 68.47M
- Float Shares
- 47.37M
of shares held by institutions
161 13F filers
Buy/sell ratio 1.44. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Essex Woodlands Management, Inc. | 13.02M | 0 |
| Juniper Investment Company, LLC | 6.94M | 0 |
| Nantahala Capital Management, LLC | 6.42M | ▲ 420.61K |
| Blackrock, Inc. | 3.41M | ▼ 24.29K |
| Vanguard Group Inc | 2.98M | ▲ 60.14K |
| American Century Companies Inc | 2.16M | ▲ 809.01K |
| Vanguard Capital Management LLC | 1.73M | ▼ 22.37K |
| Royce & Associates LP | 1.61M | ▼ 224.05K |
| Geode Capital Management, LLC | 1.39M | ▲ 24.52K |
| Dimensional Fund Advisors LP | 1.24M | ▲ 108.15K |
| State Street Corp | 1.17M | ▲ 67.12K |
| Hillsdale Investment Management Inc. | 909.74K | ▲ 2.00K |
Held by 159 ETFs
Biggest fund positions in BVS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 2, 26 | Bartholdson John A. | other | 32,282 |
| Jun 3, 26 | Bartholdson John A. | other | 25,146 |
| Jun 2, 26 | Bartholdson John A. | other | 32,282 |
| Jun 2, 26 | SUTTER MARTIN P | other | 32,282 |
| Jun 3, 26 | SUTTER MARTIN P | other | 25,146 |
| Jun 2, 26 | SUTTER MARTIN P | other | 32,282 |
| Jun 2, 26 | STALNECKER SUSAN M | other | 32,282 |
| Jun 3, 26 | STALNECKER SUSAN M | other | 25,146 |
| Jun 2, 26 | STALNECKER SUSAN M | other | 32,282 |
| Jun 2, 26 | NOHRA GUY P | other | 32,282 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BVS coverage
Recent articles, reports, and earnings notes.
Want a deeper read on BVS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Bioventus Inc. (BVS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
Bioventus (BVS) Matches Q3 Earnings Estimates
zacks.com · Nov 2
Bioventus Q3 Earnings Call Highlights
marketbeat.com · Nov 2
Bioventus Reports Third Quarter Financial Results
globenewswire.com · Nov 2
Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026
globenewswire.com · Oct 27
Bioventus Inc (BVS) Stock Up 3.6% but GF Value Says Overvalued -- GF Score: 63/100
gurufocus.com · Oct 12
Comparing Kestra Medical Technologies (NASDAQ:KMTS) & Bioventus (NASDAQ:BVS)
defenseworld.net · Oct 12
Reviewing Bioventus (NASDAQ:BVS) & RxSight (NASDAQ:RXST)
defenseworld.net · Oct 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
